Citations (28)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Yunsuk Koh, Heidi Bidstrup & David L Nichols. (2014) Niacin increased glucose, insulin, and C-peptide levels in sedentary nondiabetic postmenopausal women. International Journal of Women's Health 6, pages 913-920.
Read now
Read now
James M. McKenney. (2012) Combination Treatment with Atorvastatin plus Niacin Provides Effective Control of Complex Dyslipidemias: A Literature Review. Postgraduate Medicine 124:1, pages 7-20.
Read now
Read now
Anbu Pandian, Anjali Arora, Laurence S Sperling & Bobby V Khan. (2008) Targeting mulitple dyslipidemias with fixed combinations – focus on extended release niacin and simvastatin. Vascular Health and Risk Management 4:5, pages 1001-1009.
Read now
Read now
Articles from other publishers (25)
Irina ShalaurovaMargery A. ConnellyW. Timothy GarveyJames D. Otvos. (2014) Lipoprotein Insulin Resistance Index: A Lipoprotein Particle–Derived Measure of Insulin Resistance. Metabolic Syndrome and Related Disorders 12:8, pages 422-429.
Crossref
Crossref
Henry A. Tran, Arthur Z. Schwartzbard & James A. Underberg. 2014. Lipoproteins in Diabetes Mellitus. Lipoproteins in Diabetes Mellitus
399
413
.
Kieren J. Mather. (2013) The vascular endothelium in diabetes—a therapeutic target?. Reviews in Endocrine and Metabolic Disorders 14:1, pages 87-99.
Crossref
Crossref
Binh An P. Phan, Luis Muñoz, Pey Shadzi, Daniel Isquith, Michael Triller, B. Greg Brown & Xue-Qiao Zhao. (2013) Effects of Niacin on Glucose Levels, Coronary Stenosis Progression, and Clinical Events in Subjects With Normal Baseline Glucose Levels (<100 mg/dl): A Combined Analysis of the Familial Atherosclerosis Treatment Study (FATS), HDL-Atherosclerosis Treatment Study (HATS), Armed Forces Regression Study (AFREGS), and Carotid Plaque Composition by MRI During Lipid-Lowering (CPC) Study. The American Journal of Cardiology 111:3, pages 352-355.
Crossref
Crossref
Janet E. DigbyNeil RupareliaRobin P. Choudhury. (2012) Niacin in Cardiovascular Disease: Recent Preclinical and Clinical Developments. Arteriosclerosis, Thrombosis, and Vascular Biology 32:3, pages 582-588.
Crossref
Crossref
Baishali M. Ambegaonkar, Chuck Wentworth, Christopher Allen & Vasilisa Sazonov. (2011) Association between extended-release niacin treatment and glycemic control in patients with type 2 diabetes mellitus: analysis of an administrative-claims database. Metabolism 60:7, pages 1038-1044.
Crossref
Crossref
Young Taek OhKi-Sook OhYong Min Choi, Anne Jokiaho, Casey Donovan, Sangdun Choi, Insug KangJang H. Youn. (2011) Continuous 24-h nicotinic acid infusion in rats causes FFA rebound and insulin resistance by altering gene expression and basal lipolysis in adipose tissue. American Journal of Physiology-Endocrinology and Metabolism 300:6, pages E1012-E1021.
Crossref
Crossref
Axel Linke, Melanie Sonnabend, Mathias Fasshauer, Robert Höllriegel, Gerhard Schuler, Josef Niebauer, Michael Stumvoll & Matthias Blüher. (2009) Effects of extended-release niacin on lipid profile and adipocyte biology in patients with impaired glucose tolerance. Atherosclerosis 205:1, pages 207-213.
Crossref
Crossref
Sabine Westphal & Claus Luley. (2008) Preferential increase in high-molecular weight adiponectin after niacin. Atherosclerosis 198:1, pages 179-183.
Crossref
Crossref
Ronald B. Goldberg & Terry A. Jacobson. (2008) Effects of Niacin on Glucose Control in Patients With Dyslipidemia. Mayo Clinic Proceedings 83:4, pages 470-478.
Crossref
Crossref
John R. Guyton. 2008. Type 2 Diabetes Mellitus. Type 2 Diabetes Mellitus
265
288
.
Alberto ZambonKenneth Cusi. (2016) The role of fenofibrate in clinical practice. Diabetes and Vascular Disease Research 4:3_suppl, pages S15-S20.
Crossref
Crossref
John R Guyton. (2007) Niacin in cardiovascular prevention: mechanisms, efficacy, and safety. Current Opinion in Lipidology 18:4, pages 415-420.
Crossref
Crossref
Sabine Westphal, Katrin Borucki, Elena Taneva, Ruma Makarova & Claus Luley. (2007) Extended-release niacin raises adiponectin and leptin. Atherosclerosis 193:2, pages 361-365.
Crossref
Crossref
Francesca Vittone, Alan Chait, Josh S. Morse, Brian Fish, B. Greg Brown & Xue-Qiao Zhao. (2007) Niacin plus simvastatin reduces coronary stenosis progression among patients with metabolic syndrome despite a modest increase in insulin resistance: A subgroup analysis of the HDL-Atherosclerosis treatment study. Journal of Clinical Lipidology 1:3, pages 203-210.
Crossref
Crossref
Kenneth Cusi, Sangeeta Kashyap, Amalia Gastaldelli, Mandeep Bajaj & Eugenio Cersosimo. (2007) Effects on insulin secretion and insulin action of a 48-h reduction of plasma free fatty acids with acipimox in nondiabetic subjects genetically predisposed to type 2 diabetes. American Journal of Physiology-Endocrinology and Metabolism 292:6, pages E1775-E1781.
Crossref
Crossref
John R. Guyton & Harold E. Bays. (2007) Safety Considerations with Niacin Therapy. The American Journal of Cardiology 99:6, pages S22-S31.
Crossref
Crossref
Sabine Westphal, Katrin Borucki, Elena Taneva, Ruma Makarova & Claus Luley. (2006) Adipokines and treatment with niacin. Metabolism 55:10, pages 1283-1285.
Crossref
Crossref
Gloria Lena Vega, Nilo B. Cater, Shinishi Meguro & Scott M. Grundy. (2005) Influence of Extended-Release Nicotinic Acid on Nonesterified Fatty Acid Flux in the Metabolic Syndrome With Atherogenic Dyslipidemia. The American Journal of Cardiology 95:11, pages 1309-1313.
Crossref
Crossref
Richard J Woodman, Gerard T Chew & Gerald F Watts. (2005) Mechanisms, Significance and Treatment of Vascular Dysfunction in Type 2 Diabetes Mellitus. Drugs 65:1, pages 31-74.
Crossref
Crossref
Robert S Rosenson & Charles A Reasner. (2004) Therapeutic approaches in the prevention of cardiovascular disease in metabolic syndrome and in patients with type 2 diabetes. Current Opinion in Cardiology 19:5, pages 480-487.
Crossref
Crossref
Michael Miller. (2003) Niacin as a Component of Combination Therapy for Dyslipidemia. Mayo Clinic Proceedings 78:6, pages 735-742.
Crossref
Crossref
Ann M Poynten, Seng Khee Gan, Adamandia D Kriketos, Anthony O’Sullivan, John J Kelly, Bronwyn A Ellis, Donald J Chisholm & Lesley V Campbell. (2003) Nicotinic acid-induced insulin resistance is related to increased circulating fatty acids and fat oxidation but not muscle lipid content. Metabolism 52:6, pages 699-704.
Crossref
Crossref
M.F. McCarty. (2000) Co-administration of equimolar doses of betaine may alleviate the hepatotoxic risk associated with niacin therapy. Medical Hypotheses 55:3, pages 189-194.
Crossref
Crossref
John N. Clore, Paul A. Harris, Jing Li, Amin Azzam, Ranjodh Gill, Wilhelm Zuelzer, William B. Rizzo & William G. Blackard. (2000) Changes in phsophatidylcholine fatty acid composition are associated with altered skeletal muscle insulin responsiveness in normal man. Metabolism 49:2, pages 232-238.
Crossref
Crossref